SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $229,000 | -24.9% | 4,039 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $305,000 | -5.6% | 4,071 | +9.2% | 0.00% | 0.0% |
| Q4 2020 | $323,000 | +41.7% | 3,729 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $228,000 | -32.5% | 3,729 | -20.3% | 0.00% | -50.0% |
| Q4 2019 | $338,000 | -49.9% | 4,676 | -2.7% | 0.00% | -50.0% |
| Q3 2019 | $674,000 | -30.2% | 4,807 | -8.9% | 0.00% | -20.0% |
| Q2 2019 | $966,000 | +12.2% | 5,274 | -2.6% | 0.01% | +25.0% |
| Q1 2019 | $861,000 | +274.3% | 5,413 | +125.2% | 0.00% | +300.0% |
| Q4 2018 | $230,000 | -38.5% | 2,404 | -9.2% | 0.00% | -50.0% |
| Q3 2018 | $374,000 | -63.5% | 2,648 | -59.6% | 0.00% | -66.7% |
| Q2 2018 | $1,025,000 | +128.8% | 6,551 | +135.6% | 0.01% | +100.0% |
| Q1 2018 | $448,000 | -7.6% | 2,780 | -5.5% | 0.00% | 0.0% |
| Q4 2017 | $485,000 | – | 2,942 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |